Palavras-chave
vacina
COVID-19
Como Citar
Resumo
A Síndrome de Guillain-Barré (SGB) é uma polirradiculoneuropatia inflamatória aguda associada a processos infecciosos e, em alguns casos, a imunizações. Com o avanço da vacinação contra a COVID-19, surgiram relatos sobre a possível relação entre a imunização e o desenvolvimento da SGB. Este estudo realizou uma revisão integrativa da literatura para analisar a incidência da SGB em indivíduos vacinados contra a COVID-19. Foram pesquisados artigos publicados entre 2020 e 2024 nas bases EMBASE, Medline/PubMed, Cochrane Library, Science Direct e Scielo, utilizando descritores relacionados à síndrome e à vacinação. Após a aplicação dos critérios de inclusão e exclusão, 16 artigos foram analisados. Os resultados sugerem que algumas vacinas, especialmente as de vetor viral, podem apresentar uma maior associação com o desenvolvimento da SGB, ainda que a relação causal não esteja completamente esclarecida. Estudos epidemiológicos adicionais são necessários para compreender os mecanismos imunológicos envolvidos e garantir a segurança das vacinas.
Referências
ABUAWWAD, M. T. et al. Guillain-Barré syndrome after COVID-19 vaccination: A systematic review and analysis of case reports. Clinical Neurology and Neurosurgery, v. 238, p. 108183, mar. 2024.
BARDIN, L. Análise de conteúdo. São Paulo: Edições 70, 2011.
CENSI, S. et al. Guillain–Barré syndrome and COVID-19 vaccination: a systematic review and meta-analysis. Journal of Neurology, v. 271, n. 3, p. 1063–1071, mar. 2024.
CHEN, W.-H. et al. The SARS-CoV-2 Vaccine Pipeline: an Overview. Current Tropical Medicine Reports, v. 7, n. 2, p. 61–64, jun. 2020.
CHEN, Y. et al. New‐onset autoimmune phenomena post‐COVID‐19 vaccination. Immunology, v. 165, n. 4, p. 386–401, abr. 2022.
CHOI, M. J. et al. Comparative safety analysis of mRNA and adenoviral vector COVID-19 vaccines: a nationwide cohort study using an emulated target trial approach. Clinical Microbiology and Infection, v. 30, n. 5, p. 646–652, maio 2024.
DONG, E.; DU, H.; GARDNER, L. An interactive web-based dashboard to track COVID-19 in real time. The Lancet Infectious Diseases, v. 20, n. 5, p. 533–534, maio 2020.
FINSTERER, J.; MATOVU, D.; SCORZA, F. A. SARS-CoV-2 vaccinations reduce the prevalence of post-COVID Guillain-Barre syndrome. Clinics, v. 77, p. 100064, jan. 2022.
FINSTERER, J.; SCORZA, C. A.; SCORZA, F. A. Guillain-Barre syndrome related to SARS-CoV-2 vaccinations. Clinics, v. 77, p. 100113, jan. 2022.
FINSTERER, J.; SCORZA, F. A. Guillain-Barre syndrome in 220 patients with COVID-19. The Egyptian Journal of Neurology, Psychiatry and Neurosurgery, v. 57, n. 1, p. 55, dez. 2021.
GALASSI, G.; ARIATTI, A. Comment on “Neuromuscular complications after COVID-19 vaccination: a series of eight patients” by Leemans et al. Acta Neurologica Belgica, v. 123, n. 4, p. 1605–1606, ago. 2023.
GALLO, K. et al. A Comparative Analysis of COVID-19 Vaccines Based on over 580,000 Cases from the Vaccination Adverse Event Reporting System. Vaccines, v. 10, n. 3, p. 408, 8 mar. 2022.
GERMANO, F. et al. COVID-19 vaccine-related Guillain-Barré syndrome in the Liguria region of Italy: A multicenter case series. Journal of the Neurological Sciences, v. 440, p. 120330, 15 set. 2022.
GOUD, R. et al. Risk of Guillain-Barré Syndrome Following Recombinant Zoster Vaccine in Medicare Beneficiaries. JAMA Internal Medicine, v. 181, n. 12, p. 1623, 1 dez. 2021.
GUPTA, A. et al. Rehabilitation outcomes in patients with post-COVID-19 vaccine-associated Guillain-Barre syndrome. Journal of Neurosciences in Rural Practice, v. 13, p. 684–690, 2 dez. 2022.
HAFSTEINSDÓTTIR, B. et al. Decreased Incidence of Guillain-Barré Syndrome during the COVID-19 Pandemic: A Retrospective Population-Based Study. Neuroepidemiology, v. 57, n. 1, p. 1–6, 2023.
KARIMI, N. et al. Guillain-Barre Syndrome and COVID-19 Vaccine: A Report of Nine Patients. Basic and Clinical Neuroscience Journal, v. 12, n. 5, p. 703–710, 1 set. 2021.
KHAN, S. A. et al. An updated review on Guillain-Barré syndrome: Challenges in infection prevention and control in low- and middle-income countries. SAGE Open Medicine, v. 12, p. 20503121241239538, jan. 2024.
LANGMUIR, A. D. et al. AN EPIDEMIOLOGIC AND CLINICAL EVALUATION OF GUILLAIN-BARRÉ SYNDROME REPORTED IN ASSOCIATION WITH THE ADMINISTRATION OF SWINE INFLUENZA VACCINES. American Journal of Epidemiology, v. 119, n. 6, p. 841–879, jun. 1984.
LOGUNOV, D. Y. et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. The Lancet, v. 396, n. 10255, p. 887–897, set. 2020.
LÓPEZ-HERNÁNDEZ, J. et al. Guillain-Barré syndrome following SARS-CoV-2 vaccination: Is there a real association? Neuroimmunology Reports, v. 2, p. 100050, 2022.
MARAMATTOM, B. V. et al. Guillain‐Barré Syndrome following ChAdOx1‐S / nCoV ‐19 Vaccine. Annals of Neurology, v. 90, n. 2, p. 312–314, ago. 2021.
MUKHERJEE, R. Global efforts on vaccines for COVID-19: Since, sooner or later, we all will catch the coronavirus. Journal of Biosciences, v. 45, n. 1, p. 68, dez. 2020.
PLOTKIN, S. A. Vaccines: Correlates of Vaccine‐Induced Immunity. Clinical Infectious Diseases, v. 47, n. 3, p. 401–409, ago. 2008.
POLACK, F. P. et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. New England Journal of Medicine, v. 383, n. 27, p. 2603–2615, 31 dez. 2020.
RESTREPO-VERA, J. L. et al. Immunological, Clinical, and Epidemiological Features of Guillain-Barré Syndrome Associated with SARS-CoV-2 Infection. Acta Neurologica Scandinavica, v. 2023, p. 1–9, 7 fev. 2023.
RODRÍGUEZ, Y. et al. Autoimmune and autoinflammatory conditions after COVID-19 vaccination. New case reports and updated literature review. Journal of Autoimmunity, v. 132, p. 102898, out. 2022.
RZYMSKI, P. Guillain-Barré syndrome and COVID-19 vaccines: focus on adenoviral vectors. Frontiers in Immunology, v. 14, p. 1183258, 26 abr. 2023.
SALSONE, M. et al. NEURO-COVAX: An Italian Population-Based Study of Neurological Complications after COVID-19 Vaccinations. Vaccines, v. 11, n. 10, p. 1621, 21 out. 2023.
TAGA, A.; LAURIA, G. COVID ‐19 and the peripheral nervous system. A 2‐year review from the pandemic to the vaccine era. Journal of the Peripheral Nervous System, v. 27, n. 1, p. 4–30, mar. 2022.
VELLOZZI, C.; IQBAL, S.; BRODER, K. Guillain-Barre Syndrome, Influenza, and Influenza Vaccination: The Epidemiologic Evidence. Clinical Infectious Diseases, v. 58, n. 8, p. 1149–1155, 15 abr. 2014.
WILLISON, H. J.; JACOBS, B. C.; VAN DOORN, P. A. Guillain-Barré syndrome. The Lancet, v. 388, n. 10045, p. 717–727, ago. 2016.
YEPES, M. Neurological Complications of SARS-CoV-2 Infection and COVID-19Vaccines: From Molecular Mechanisms to Clinical Manifestations. Current Drug Targets, v. 23, n. 17, p. 1620–1638, dez. 2022.
YUKI, N.; HARTUNG, H.-P. Guillain–Barré Syndrome. New England Journal of Medicine, v. 366, n. 24, p. 2294–2304, 14 jun. 2012.
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Copyright (c) 2025 Luis Guilherme de Sousa Silva, Ana Luíza Quevedo, Patrícia Pinto Saraiva, Rosemeire Simone Dellacrode Giovanazzi